Hüppa põhisisu juurde
Raamatukoi
Tõde ja õigus

Regulatory Processes for Rare Disease Drugs in the United States and European Union

Flexibilities and Collaborative Opportunities

Engineering and Medicine National Academies of Sciences, Health and Medicine Division, Board on Health Sciences Policy, Committee on Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union · National Academies Press · 2024

Regulatory Processes for Rare Disease Drugs in the United States and European Union

Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.

Saadavus
43,50 €

Uus kasutamata raamat

Täna tellides on tarneaeg umbes 9 päeva (27.11.2026)Tellimuse täitmise aeg on umbkaudne ja sõltub nädalapäevast, millal tellimus tehakse. Reeglina ei kulu üle kahe nädala.

Tarne ja kättesaamine

Detailid

Alapealkiri
Flexibilities and Collaborative Opportunities
ISBN
9780309726559
Aasta
2024
Keel
inglise
Köide
Pehme kaas
Lehekülgi
386
Teema
Meditsiin — Medicine
Kaal
628 g